Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $3.86

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $3.8571.

A number of research analysts recently issued reports on RVPH shares. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. D. Boral Capital reissued a “buy” rating and issued a $2.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Finally, Benchmark decreased their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th.

Reviva Pharmaceuticals Stock Down 5.4%

Shares of RVPH stock opened at $0.29 on Friday. Reviva Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $2.17. The stock’s fifty day simple moving average is $0.55 and its 200 day simple moving average is $0.50. The firm has a market capitalization of $33.39 million, a P/E ratio of -0.63 and a beta of -0.02.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. As a group, equities research analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the period. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals during the first quarter valued at $58,000. XTX Topco Ltd acquired a new stake in Reviva Pharmaceuticals during the 2nd quarter worth about $31,000. Lido Advisors LLC acquired a new stake in Reviva Pharmaceuticals during the 3rd quarter worth about $37,000. Finally, Millennium Management LLC raised its position in shares of Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after acquiring an additional 223,178 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.